Normalisation of physical function by infliximab in patients with RA: Factors associated with normal physical function

Clinical and Experimental Rheumatology

Volumn 28, Issue 3, 2010, Pages 365-372

  Nagasawa, Hayato ^a   Kameda, Hideto ^b   Sekiguchi, Naoya ^a   Amano, Koichi ^a   Takeuchi, Tsutomu ^a,b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Disease Activity Score of 28 joints (DAS28); Health Assessment Questionnaire Disability Index (HAQ DI); Infliximab; Rheumatoid arthritis; Van der Heijde modification of the Sharp score (vdH Sharp score)

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; STROMELYSIN; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE 28; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; JOINT INJURY; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VAN DER HEIJDE MODIFIED SHARP SCORE; CLINICAL TRIAL; CONVALESCENCE; DISABILITY; DRUG EFFECT; FOLLOW UP; HOSPITALIZATION; LONGITUDINAL STUDY; MIDDLE AGED; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOTOR ACTIVITY; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 77957014531     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. th ed: McGraw-Hill; 2001: 1928-37.
2. FRIES JF, SPITZ P, KRAINES RG, HOLMAN HR: Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
3. BRUCE B, FRIES JF: The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003; 30: 167-78.
4. PINCUS T, SUMMEY JA, SORACI SA, WALLSTON KA, HUMMON NP: Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis Rheum 1983; 26: 1346-53.
5. PINCUS T, SOKKA T: Quantitative target values of predictors mortality in rheumatoid arthritis as possible goals for therapeutic interventions: an alternative approach to remission or ACR20 responses? J Rheumatol 2001; 28: 1723-34.
6. SOKKA T, PINCUS T: Markers for work disability in rheumatoid arthritis. J Rheumatol 2001; 28: 1718-22.
7. WELSING PMJ, VAN GESTEL AM. SWINKEL HL, KIEMENCY LALM, VAN RIEL PLCM: The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2009-17.
8. DROSSAERS-BAKKER KW, DE BUCK M, VAN ZEBEN D, ZWINDERMAN AH, BREEDVELD FC, HAZES JMW: Long-term course and outcome of functional capacity in rheumatoid arthritis. Arthritis Rheum 1999; 42: 1854-60.
9. SCOTT DL, PUGNER K, KAARELA K et al.: The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000; 39: 122-32.
10. GUILLEMIN F, BRIANCON S, POUREL J: Functional disability in rheumatoid arthritis: two different models in early and established disease. J Rheumatol 1992; 19: 366-9.
11. NAGASAWA H, KAMEDA H, SEKIGUCHI N, AMANO K, TAKEUCHI T: Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction. Mod Rheumatol 2009; 19: 166-72.
12. SALAFFI F, CIMMINO MA, LEARDINI G, GASPARlNI S, GRASSI W: Disease activity assessment of rheumatoid arthritis in daily practice: validity, internal consistency, reliability and congruency of the Disease Activity Score including 28 joints (DAS28) compared with the Clinical Disease Activity Index (CDAI). Clin Exp Rheumatol 2009; 27: 552-9.
13. FELDMANN M, BRENNAN FM, MAINI RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440.
14. IVASHKIV LB: Cytokine expression and cell activation in inflammatory arthritis. Adv Immunol 1996; 63: 337-76.
15. CHOY EH, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.
16. BREEDVELD FC, EMERY P, KEYSTONE E et al.: Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004; 63: 149-55.
17. ST CLAIR EW, VAN DER HEIJDE DM, SMOLEN JS et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43.
18. GOEKOOP-RUITERMAN YPM, DE VRIESBOUWSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2004; 52: 3381-90.
19. QUINN MA, CONAGHAN PG, O'CONNOR PJ et al.: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 27-35.
20. VIRKKI LM, KONTTINEN YT, PELTOMAA R et al.: Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 2008; 26: 1059-66.
21. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
22. KOIKE R, TAKEUCHI T, EGUCHI K, MIYASAKA N; JAPAN COLLEGE OF RHEUMATOLOGY: Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 2007; 17: 451-8.
23. PREVOO ML, VAN'T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
24. HUBERT HB, BLOCH DA, FRIES JF: Risk factors for physical disability in an aging cohort: the NHANES I epidemiologic follow-up study. J Rheumatol 1993; 20: 480-8.
25. BRUCE B, FRIES JF: The Stanford Health Assessment Questionnaire: dimensions of practical applications. Health Qual Life Outcomes 2003; 1: 20.
26. VAN DER HEIJDE D, LASSERE M, EDMONDS J, KIRWAN J, STRAND V, BOERS M: Minimal clinically important difference in plain films in RA: group discussions, conclusions, and recommendations OMERACT Imaging Task Force. J Rheumatol 2001; 28: 914-7.
27. PEASE CT, BHAKTA BB, DEVLIN J, EMERY P: Does the age of onset of rheumatoid arthritis influence phenotype? A prospective study of outcome and prognostic factors. Rheumatology (Oxford) 1999; 38: 228-34.
28. VLIET VLIELAND TP, BUTTENHUIS NA, VAN ZEBEN D, VANDENBROUCKE JP, BREEDVELD FC, HAZES JM: Sociodemographic factors and the outcome of rheumatoid arthritis in young women. Ann Rheum Dis 1994; 53: 803-6.
29. WARD MM, LEIGH JP: The relative importance of pain and functional disability to patients with rheumatoid arthritis. J Rheumatol 1993; 20: 1494-9.
30. WOLFE F, HAWLEY DJ, WILSON K: The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996; 23: 1407-17.
31. WOLFE F, HAWLEY DJ: The relationship between clinical activity and depression in rheumatoid arthritis. J Rheumatol 1993; 20: 2032-7.
32. ABDEL-NASSER AM, EL-AZIM S, TAAL E, EL-BADAWY SA, RASKER JJ, VALKENBURG HA: Depression and depressive symptoms in rheumatoid arthritis patients: an analysis of their occurrence and determinants. Br J Rheumatol 1998; 37: 391-7.
33. UUTELA T, HANNONEN P, KAUTIAINEN H, HAKALA M, PAANANEN ML, HÄKKINEN A: Positive treatment response improves the health-related quality of life of patients with early rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 108-11.
34. ALLAIRE S, WOLFE F, NIU J, ZHANG Y, ZHANG B, LAVALLEY M: Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum 2008; 59: 1082-9.
35. WELLS GA, BOERS M, SHEA B et al.: Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005 Oct; 32: 2016-24.
36. KHANNA D, OH M, FURST DE et al:, WESTERN CONSORTIUM OF PRACTICING RHEUMATOLOGISTS: Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum 2007; 57: 440-7.
37. WOLFE F: A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2751-61.
38. SOKKA T, KANKAINEN A, HANNONEN P: Scores for functional disability in patients with rheumatoid arthritis are correlated at higher levels with pain scores than with radiographic scores. Arthritis Rheum 2000; 43: 386-9.
39. BREEDVELD FC, HAN C, BALA M et al.: Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 52-5.
40. CLARKE AE, ST-PIERRE Y, JOSEPH L, PENROD JT, SIBLEY MH, GENANT HK: Radiographic damage in rheumatoid arthritis correlates with functional disability but not direct medical costs. J Rheumatol 2001; 28: 2416-24.
41. KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
42. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
43. ALETAHA D, SMOLEN J, WARD MM: Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006; 54: 2784-92.
44. SMOLEN JS, ALETAHA D, GRISAR JC, STAMM TA and SHARPJT: arthritis clinical trialsdam-age-related physical disability in rheumatoid Estimation of a numerical value for joint. Ann Rheum Dis 2009 Epub 27 Aug.
45. RAMOS-REMUS, VALENTINI G, ZOCHLING J, DOUGADOS MIELANTS M et al.: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68; 1086-93.
46. KLIMIUK PA, SIERAKOWSKI S, DOMYSLAWSKA I, CHWIECKO J: Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 238-4.
47. HYRICH KL, WATSON KD, SILMAN AJ, SYMMONS DP: Predictors of response to antiTNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006; 45: 1558-65.
48. MANCARELLA L, BOBBIO-PALLAVICINI F, CECCARELLI F et al.: Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 2007; 341670-3.
49. KAMEDA H, SEKIGUCHI N, NAGASAWA H et al.: Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab. Mod Rheumatol 2006; 16: 381-8.
50. SARAUX A, DEVAUCHELLE-PENSEC V, ENGERRAN L, FLIPO RM: Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: results of the PRISME survey. J Rheumatol 2006; 33: 1258-65.